Mirati Therapeutics, Inc. (MRTX) Social Stream



Mirati Therapeutics, Inc. (MRTX): $68.16

2.27 (+3.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 396

in industry

Featured Post From StockTwits About MRTX

$KDMN, pegged at $500m annual peak sales and significant improvement in quality of life for chronic GVHD patients (meaning payers will provide coverage).

"Patients receiving [belumosudil] reported significant improvements in chronic GVHD symptoms, showing that not only did treatment result in organ responses, but it also made people feel better. This is so important for a chronic disease with a high symptom burden," Stephanie Lee, MD, MPH, professor at the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, and research director of the Long-Term Follow-Up Program at Fred Hutchinson, noted in the release.

https://www.targetedonc.com/view/fda-approves-belumosudil-for-chronic-graft-versus-host-disease

$MRTX $GTHX $KPTI
Jasooon, published July 17, 2021

What Else are MRTX Traders Talking About?


Other tickers frequently mentioned alongside MRTX are KDMN, GTHX and KPTI.

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4195 seconds.